anidulafungin, Eraxis

 Indications

Candidemia and other serious candidal infections including

intra-abdominal abscess, peritonitis. Esophageal

candidiasis.

Action

Inhibits the synthesis of fungal cell wall. Therapeutic

Effects: Death of susceptible fungi. Spectrum: Active

against Candida albicans, C. glabrata, C. parapsilosis,

and C. tropicalis.

Pharmacokinetics

Absorption: IV administration results in complete

bioavailability.

Distribution: Crosses the placenta.

Metabolism and Excretion: Undergoes chemical

degradation without hepatic metabolism; 1% excreted

in urine.

Half-life: 40–50 hr.

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION

IV rapid end of infusion

24 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity.

Use Cautiously in: Underlying liver disease (may

worsen); OB, Lactation: Pregnancy or lactation; Pedi:

Safety not established.

Adverse Reactions/Side Effects

Resp: bronchospasm, dyspnea. CV: hypotension. GI:

diarrhea,qliver enzymes. Derm: flushing, rash, urticaria.

F and E: hypokalemia. Misc: ANAPHYLAXIS, infusion

reaction.

Interactions

Drug-Drug: None noted.

Route/Dosage

IV (Adults): Esophageal candidiasis—100 mg loading

dose on day 1, then 50 mg daily. Candidemia and

other candidal infections—200 mg loading dose on

day 1, then 100 mg daily.

Availability

Lyophilized powder for IV use (requires reconstitution):

50 mg/vial.